Medulloblastoma Forms Symbiotic Metabolic Partnerships with Macrophages to Establish Leptomeningeal Metastases.
This preprint reports that progression of medulloblastoma leptomeningeal metastases is supported by a CXCL12-driven partnership in which recruited lipid-laden macrophages export cholesterol through ABCG1 for tumor-cell uptake through SCARB1, with dietary fat and pathway interventions altering progression in vivo.
Open original publication →What the AI sees
This preprint reports that progression of medulloblastoma leptomeningeal metastases is supported by a CXCL12-driven partnership in which recruited lipid-laden macrophages export cholesterol through ABCG1 for tumor-cell uptake through SCARB1, with dietary fat and pathway interventions altering progression in vivo.
Research significance
The supplied abstract provides in-vivo evidence that CXCL12-mediated macrophage recruitment and exogenous cholesterol are necessary and sufficient for metastatic progression; it therefore supports—but does not clinically validate—the hypothesis that dietary modulation or pharmacologic inhibition of the CXCL12–ABCG1–SCARB1 cholesterol-transfer axis could prevent or treat medulloblastoma leptomeningeal metastases.
Source abstract
Leptomeningeal metastases are the primary source of morbidity and mortality for pediatric medulloblastoma patients. Due to limited surgical sampling of metastases in patients, little is understood of the mechanisms of metastasis. Here, we identify biologically distinct quiescent small metastases (designated as micrometastases) and mitotically active larger metastases (macrometastases). Macrometastases are more metabolically active than micrometastases and contain higher levels of lipids, particularly cholesterol. Macrometastases secrete CXCL12, which attracts lipid-laden macrophages into the tumor. Lipid-laden macrophages upregulate the cholesterol transporter ABCG1, promoting the efflux of free cholesterol, which is then taken up by tumor cells via the HDL receptor SCARB1. CXCL12-driven macrophage recruitment and exogenous cholesterol are sufficient and necessary to drive progression of medulloblastoma leptomeningeal metastases in vivo. High fat diets drive metastatic progression in vivo. Dietary or pharmacological interventions targeting the CXCL12-SCARB1-cholesterol axis represent therapeutic strategies to either prevent or treat medulloblastoma leptomeningeal metastases.